Positive impactResults
Laurus Labs, Gland Pharma, Piramal, Divi's Labs: 4 drug manufacturing stocks rally up to 89% in 6 months - Upside ahead?
Mint 1 hr ago·12 Nov 2026, 4:49 pm
Gland Pharma has surged nearly 80% over the last six months, leading a rally among Indian drug manufacturers. This sharp rise is driven by strong investor optimism regarding the company's quarterly performance and its position in the global Contract Development and Manufacturing Organization (CDMO) sector.
For investors, this momentum highlights the sector's resilience and the potential for sustained growth in pharmaceutical manufacturing. The rally suggests that market participants are confident in the company's ability to execute and capture opportunities in the international market.
Moving forward, investors should monitor the company's upcoming quarterly results and its ability to maintain this growth trajectory amidst global economic conditions.
Excerpt from Mint
Pharma stocks, particularly CDMO companies, have surged over the past six months amid optimism about quarterly results. Laurus Labs led with an 88.64% gain, followed by Gland Pharma at 80.36%, Divi’s Laboratories at 72.35% and Piramal Pharma at 38.65%. Pharma stocks have emerged as the star performers of Dalal Street…Read the original at Mint
Affected stocks
Bullish4 stocks
Gland Pharma
GLAND Bullish
₹3,308.70
LAURUSLABS
LAURUSLABS Bullish
—
DIVISLAB
DIVISLAB Bullish
—
PPLPHARMA
PPLPHARMA Bullish
—
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Gland Pharma (GLAND).
- Category: Results.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
- Also mentions LAURUSLABS, DIVISLAB, PPLPHARMA.
Why it matters
A meaningful update for Gland Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
